This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0.00% and 34.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MEI Pharma, Inc. (MEIP) Reports Break-Even Earnings for Q4
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 100.00% and 95.18%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Mei (MEIP) Begins Phase III Study for B-Cell Malignancies
by Zacks Equity Research
Mei Pharma (MEIP) doses first patient in phase III study to evaluate zandelisib plus rituximab in follicular lymphoma or marginal zone lymphoma.
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -33.33% and -46.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate MEI Pharma, Inc. (MEIP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -46.67% and 340.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.
Ampio Pharmaceuticals (AMPE) Jumps: Stock Rises 8.7%
by Zacks Equity Research
Ampio Pharmaceuticals (AMPE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment
by Zacks Equity Research
Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.
Zacks.com featured highlights include: YIN, CALX, OOMA and MEIP
by Zacks Equity Research
Zacks.com featured highlights include: YIN, CALX, OOMA and MEIP
4 Breakout Stocks for Explosive Returns
by Nitish Marwah
The first step to selecting the right breakout stock is to calculate its support and resistance level.
Go Defensive to Beat Market Turbulence With These 4 Stocks
by Zacks Equity Research
Opting for a defensive strategy in the current market scenario could be ideal, given that the Dow just booked its worst daily drop in more than two-and-a-half-months.
Is the Options Market Predicting a Spike in MEI Pharma (MEIP) Stock?
by Zacks Equity Research
Investors need to pay close attention to MEI Pharma (MEIP) stock based on the movements in the options market lately.
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
by Kinjel Shah
Small drugmakers post impressive first-quarter results. Though second-quarter results may be severely impacted by the coronavirus pandemic, an improvement is expected in the second half.
Tap the Solid Momentum in These 5 Solid High-Beta Stocks
by Sanghamitra Saha
Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta stocks that are in high momentum should gain ahead.
How MEI Pharma (MEIP) Stock Stands Out in a Strong Industry
by Zacks Equity Research
MEI Pharma (MEIP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
MEI Pharma, Inc. (MEIP) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in MEI Pharma, Inc. (MEIP).
Top Ranked Momentum Stocks to Buy for May 15th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 15th
The Zacks Analyst Blog Highlights: Ensign, Gaia, MEI Pharma, Turning Point Brands and A10 Networks
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Ensign, Gaia, MEI Pharma, Turning Point Brands and A10 Networks
5 Top Stocks That Have Skyrocketed in the Past 7 Days
by Nalak Das
Despite the coronavirus-induced market downturn, a handful of stocks have soared in the last seven trading days defying the overall market trend.
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
New Covid-19 Cases Increase, 5 Defensive Stocks to Buy
by Zacks Equity Research
Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.
MEI Pharma (MEIP) Catches Eye: Stock Jumps 8.1%
by Zacks Equity Research
MEI Pharma (MEIP) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.